Spotlight on Pediatrics

Credits: 0.75 CME
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence
Reynold A. Panettieri, Jr., MD
Integrity Continuing Education, Inc.

Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Pediatrics Presentations

0.50 CME / MOC
Vindico
Improving Adult Vaccine Confidence: A GameOn! Challenge

Improving Adult Vaccine Confidence: A GameOn! Challenge

Start

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: August 6, 2020
Expires: August 5, 2021
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
  • Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
  • Use effective strategies to educate adult patients and increase their vaccine confidence.

Activity Description

Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.

Faculty

Activity Chair:
Charles P. Vega, MD, FAAFP

Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

  • Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD

  • Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:

  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.5 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: August 6, 2020
Expires: August 5, 2021
30 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is internists and other health care professionals involved in the management of patients in need of vaccines.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the safe and effective use of vaccination in high-risk patients, such as those who are aged 65 years or older, have significant comorbidities, or are immunocompromised.
  • Recommend vaccines to adult patients in accordance with the latest ACIP recommendations.
  • Use effective strategies to educate adult patients and increase their vaccine confidence.

Activity Description

Vaccines prevent 2 to 3 million deaths per year, yet compliance with Advisory Committee on Immunization Practices (ACIP) recommendations remains low in the United States. Recently, the Centers for Disease Control and Prevention issued a program, Vaccinate with Confidence, to protect communities at risk and strengthen public trust in vaccination. Central to this program is the need to debunk vaccine myths via education and family empowerment. In this CME activity, participants will play GameOn!, a quiz of knowledge and confidence, in which they will answer questions on the latest ACIP recommendations regarding high-risk patients and vaccination strategies for adult patients and select the level of confidence in their answers to achieve the highest score among their peers.

Faculty

Activity Chair:
Charles P. Vega, MD, FAAFP

Health Sciences Clinical Professor,
Department of Family Medicine
Executive Director,
Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA

Disclosure: No relevant financial relationships to disclose.


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

  • Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD

  • Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:

  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the questions. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.75 CME
Integrity Continuing Education, Inc.
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME / MOC
Vindico
Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME / CNE / CPE
Integrity Continuing Education, Inc.
Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Clearing the Air: Recognizing the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 25, 2020
Expires: June 25, 2021
1 hour to complete

Accredited By

This CME activity for ACCME credit is provided by Integrity Continuing Education.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education.

Target Audience

This educational initiative has been designed for pulmonologists, allergists, fellows, medical residents, nurse practitioners, physician assistants, nurses, and other allied health care professionals who manage patients with asthma and other eosinophilic-associated diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why severe asthma comorbidities and rare orphan diseases have an impact on treatment of severe asthma
  • Differentiate between available biologic therapies and evaluate their impact on lung function, asthma exacerbations, and dependence on oral corticosteroids

Activity Description

This program was designed to increase the clinician’s understanding of severe eosinophilic diseases that target the lungs and enable them to differentiate between available treatments to facilitate improved symptoms, lighter disease burden, fewer exacerbations, and reduced oral corticosteroids reliance.

Statement of Educational Need

In the area of severe asthma, an emerging understanding of disease pathophysiology has identified therapeutic targets leading to better tolerated and more selective treatments. Biologics now fill a previously unmet need for effective treatment options for patients with eosinophilic-mediated respiratory disease. However, there are a number of eosinophil-mediated lung diseases associated with severe asthma that remain poorly understood, including eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Understanding the drivers of diseases associated with and sometimes concomitant to severe asthma is critical to effective management, as is the ability to identify which patients might benefit from available therapeutic agents.

Faculty

J. Mark FitzGerald, MB, MD, FRCPC (Faculty Presenter)
Professor of Respiratory Medicine
University of British Columbia
Vancouver, British Columbia

Disclosure:
Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Fees for Non-CME/CE: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Sanofi Regeneron, Teva Pharmaceutical Industries Ltd.

Contracted Research/Funds paid directly to UBC: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Gossamer Bio, Novartis Pharmaceuticals Corporation, Sanofi Regeneron


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education (Integrity CE) and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity CE and Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following project managers/planners: Lindsay Borvansky, Ashley Cann, Donna Fausak, Andrea Funk, Amy Khalil, Liddy Knight, Ashley Marostica, RN, MSN, Patima Tanapat, PhD, reported that they or their spouses/life partners, have no financial relationships or relationships to products or devices with commercial interests related to the content of this CE activity.

Designation of Credit

Physician Credit
Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Integrity Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour(s) is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Global Education Group designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-20-069-H01-P)

This is a knowledge-based activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of June 25, 2020 through June 25, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. For pharmacist/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education and GlaxoSmithKline do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education or GlaxoSmithKline. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions about the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

For information about the ANCC or ACPE accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

0.75 CME
Vindico
What’s New in Flu? Advances in Therapeutic Options

What’s New in Flu? Advances in Therapeutic Options

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Vindico
Expanding Options in Influenza Management

Expanding Options in Influenza Management

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 CME
The France Foundation
Updates in SMA and Gene Therapy from Copenhagen

Updates in SMA and Gene Therapy from Copenhagen

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 6, 2019
Expires: December 5, 2020
50 minutes to complete

Accredited By

Target Audience 

Neurologists, pediatricians, and general practitioners

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain status of newborn testing addition to screening panel in applicable states
  • Explain the implications of new gene therapy for SMA
  • Summarize key clinical trial data on novel treatments for SMA, with a focus on gene therapy
  • Explain key aspects of new guidance documents that inform up-to-date clinical practice

Activity Description

New information on spinal muscular atrophy was presented at an international meeting. Neuromuscular specialists share their perspective on the impact of this information on patient management in short videos about gene therapy, newborn screening, and therapeutic recommendations. These videos are available for viewing in English, Spanish, French, German, or English with Japanese or Arabic subtitles. Get up-to-date in 30 minutes in your own language.

Statement of Educational Need

The rapid influx of new information surrounding treatment for SMA has created a gap in clinician knowledge and the ability to apply it to practice. 

Agenda

Video topics

  • Exciting New Results in Patients Treated with Gene Therapy
  • Gene Therapy Biodistribution Study Results
  • Future Implications for SMA Therapy
  • SMN Copy Number and SMA Treatment
  • Encouraging Data from the Risdiplam Studies
  • Disease Progression in Untreated Patients
  • Early Detection and Early Treatment is Key
  • Evolving Assessments and Emerging Phenotypes in SMA
  • Status of Newborn Screening Varies by Country
  • Managing Patients with SMA

Faculty

Diana Castro, MD
Diana Castro, MD
Pediatric Neuromuscular Specialist
University of Texas, Southwestern
Dallas, TX

Dr. Castro has done contract research for AveXis, Biogen, PTC, Sarepta, and ReveraGen BioPharma.


Andreea Seferian, MD
Andreea Seferian, MD
Pediatric Neurologist
Myology Institute
I-Motion Institute
Armand Trousseau Hospital
Paris, France

Dr. Seferian has no relevant financial relationships to disclose.


Daniel Natera de Benito, MD, PhD
Daniel Natera de Benito, MD, PhD
Neuromuscular Disorders Unit 
Pediatric Neurology Department
Hospital Sant Joan de Déu
Barcelona, Spain

Dr. Natera de Benito has no relevant financial relationships to disclose.


Laurent Servais, MD
Laurent Servais, MD
Professor of Pediatric Neuromuscular Diseases
MDUK Oxford Neuromuscular Center
University of Oxford
Oxford, United Kingdom

Dr. Servais serves on advisory boards for AveXis, Biogen, Cytokinetics, and Roche. He also does contract research for AveXis, Biogen, and Roche. 


Prof. Dr. Maggie C. Walter, MA
Prof. Dr. Maggie C. Walter, MA
Friedrich Baur Institute
Department of Neurology
Ludwig-Maximilians-University
Munich, Germany

Dr. Walter is a consultant for Ask Bio, AveXis, Pharnext, and PTC Therapeutics. She serves on the advisory boards for AveXis, Biogen, PTC Therapeutics, and Sarepta. Dr. Walter also does contract research for Pharnext and receives grant funding from Biogen, Pharnext, PTC Therapeutics, Santhera, and Sarepta.


Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 6, 2019
Expires: December 5, 2020
50 minutes to complete

Accredited By

Target Audience 

Neurologists, pediatricians, and general practitioners

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain status of newborn testing addition to screening panel in applicable states
  • Explain the implications of new gene therapy for SMA
  • Summarize key clinical trial data on novel treatments for SMA, with a focus on gene therapy
  • Explain key aspects of new guidance documents that inform up-to-date clinical practice

Activity Description

New information on spinal muscular atrophy was presented at an international meeting. Neuromuscular specialists share their perspective on the impact of this information on patient management in short videos about gene therapy, newborn screening, and therapeutic recommendations. These videos are available for viewing in English, Spanish, French, German, or English with Japanese or Arabic subtitles. Get up-to-date in 30 minutes in your own language.

Statement of Educational Need

The rapid influx of new information surrounding treatment for SMA has created a gap in clinician knowledge and the ability to apply it to practice. 

Agenda

Video topics

  • Exciting New Results in Patients Treated with Gene Therapy
  • Gene Therapy Biodistribution Study Results
  • Future Implications for SMA Therapy
  • SMN Copy Number and SMA Treatment
  • Encouraging Data from the Risdiplam Studies
  • Disease Progression in Untreated Patients
  • Early Detection and Early Treatment is Key
  • Evolving Assessments and Emerging Phenotypes in SMA
  • Status of Newborn Screening Varies by Country
  • Managing Patients with SMA

Faculty

Diana Castro, MD
Diana Castro, MD
Pediatric Neuromuscular Specialist
University of Texas, Southwestern
Dallas, TX

Dr. Castro has done contract research for AveXis, Biogen, PTC, Sarepta, and ReveraGen BioPharma.


Andreea Seferian, MD
Andreea Seferian, MD
Pediatric Neurologist
Myology Institute
I-Motion Institute
Armand Trousseau Hospital
Paris, France

Dr. Seferian has no relevant financial relationships to disclose.


Daniel Natera de Benito, MD, PhD
Daniel Natera de Benito, MD, PhD
Neuromuscular Disorders Unit 
Pediatric Neurology Department
Hospital Sant Joan de Déu
Barcelona, Spain

Dr. Natera de Benito has no relevant financial relationships to disclose.


Laurent Servais, MD
Laurent Servais, MD
Professor of Pediatric Neuromuscular Diseases
MDUK Oxford Neuromuscular Center
University of Oxford
Oxford, United Kingdom

Dr. Servais serves on advisory boards for AveXis, Biogen, Cytokinetics, and Roche. He also does contract research for AveXis, Biogen, and Roche. 


Prof. Dr. Maggie C. Walter, MA
Prof. Dr. Maggie C. Walter, MA
Friedrich Baur Institute
Department of Neurology
Ludwig-Maximilians-University
Munich, Germany

Dr. Walter is a consultant for Ask Bio, AveXis, Pharnext, and PTC Therapeutics. She serves on the advisory boards for AveXis, Biogen, PTC Therapeutics, and Sarepta. Dr. Walter also does contract research for Pharnext and receives grant funding from Biogen, Pharnext, PTC Therapeutics, Santhera, and Sarepta.


Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the online posttest. A score of at 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
  6. Credit documentation/reporting:

Statement of Commercial Support

This activity is supported by an educational grant from AveXis, Inc.

Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Disclaimer

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.